Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study.
Mohammad ShehabMohamed Abu-FarhaFatema AlrashedAhmad AlfadhliKhazna AlotaibiAbdullah AlsahliThangavel Alphonse ThanarajArshad ChannanathHamad AliJehad AbubakerFahd Al-MullaPublished in: Journal of clinical medicine (2021)
In patients with IBD receiving infliximab combination therapy, SARS-CoV2 IgG, IgA, and neutralizing antibody levels after BNT162b2 vaccination were lower compared with healthy participants. However, most patients treated with infliximab combination therapy seroconverted after two doses of the vaccine.